

Thermo Fisher, CSL to provide best-in-class pharma services

01 June 2020 | News

Thermo Fisher will support CSL's product portfolio by leveraging its pharma services network



Thermo Fisher Scientific Inc., the world leader in serving science, and Australia headquartered CSL Limited have announced they have entered into a strategic partnership to help meet the growing demand for biologic therapies while also accelerating CSL's broader manufacturing objectives.

Thermo Fisher will support CSL's product portfolio by leveraging its pharma services network, including drug product development, biologics manufacturing, sterile fill-finish, packaging and clinical trials logistics. Through a long-term lease agreement with CSL, Thermo Fisher will operate a new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland, when construction is completed in mid-2021.

Within the Lengnau site, Thermo Fisher will support manufacturing of CSL's next-generation product for hemophilia patients. The site will feature highly flexible bioproduction technologies, including single-use and stainless steel, to provide a pathway from development to large-scale production as customers' needs increase. Over time, Thermo Fisher plans to expand the use of the site to include additional biopharma customers.